ArticleInternational journal of emergency medicine2026
NSTEMI and supraventricular tachycardia post-chemotherapy: a rare cardiotoxic complication.
Article in International journal of emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced myocardial infarction (MI) is an exceptionally rare but significant complication of cancer treatment. CASE PRESENTATION: This report discusses a case of a 52-year-old patient with breast cancer who developed non-ST elevation myocardial infarction (NSTEMI) three days after receiving doxorubicin and cyclophosphamide that were her 5th cycle of chemotherapy. The diagnosis was supported by elevated troponin levels, echocardiographic findings, and electrocardiography (ECG) showing supraventricular tachycardia (SVT) with aberrancy, which was treated with cardioversion. DISCUSSION: This case highlights the importance of distinguishing chemotherapy-induced MI from other cardiotoxic effects and emphasizes the need for vigilant cardiac monitoring during cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.